048410.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:30):

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body...

Stats
Dzisiejszy wolumen	211 771
Średni wolumen	470 669
Kapitalizacja rynkowa	808.31B
EPS	KRW0 ( 2024-02-25 )
Następna data zysków	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW50.50 (0.25%)

Wolumen Korelacja

Długi: -0.11 (neutral)

Krótki: -0.17 (neutral)

Signal:(53.603) Neutral

Hyundai Bioscience Co., Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hyundai Bioscience Co., Korelacja - Waluta/Towar

-0.15
( neutral )

-0.16
( neutral )

0.06
( neutral )

-0.01
( neutral )

-0.53
( weak negative )

0.06
( neutral )

Hyundai Bioscience Co., Finanse

Annual	2023
Przychody:	KRW9.48B
Zysk brutto:	KRW3.92B (41.36 %)
EPS:	KRW-364.53

FY	2023
Przychody:	KRW9.48B
Zysk brutto:	KRW3.92B (41.36 %)
EPS:	KRW-364.53

FY	2022
Przychody:	KRW7.85B
Zysk brutto:	KRW1.95B (24.79 %)
EPS:	KRW-401.53

Financial Reports:

No articles found.

Hyundai Bioscience Co.,

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.